Bolu Abifarin is an experienced Independent Prescriber and Advanced Clinical Practitioner, providing ADHD medication to clients with a confirmed diagnosis of ADHD who meet clinical inclusion criteria. Bolu is registered with the General Pharmaceutical Council (GPhC) and the Royal Pharmaceutical Society (RPS), and is an Associate Member of the College of Mental Health Pharmacy (CMHP). He holds the V300 Independent Prescriber qualification. Bolu completed his Master of Pharmacy (MPharm) at the UCL School of Pharmacy in 2012, followed by a Postgraduate Diploma in Pharmacy Practice at the University of East Anglia in 2017, and a Postgraduate Certificate in Psychiatric Therapeutics at Aston University in 2019. He went on to complete Prescribing for Clinical Practice as an Independent Prescriber in 2021 and qualified as an Advanced Clinical Practitioner in 2022, both at London South Bank University. Bolu has over ten years' experience as a clinical pharmacist, with more than five years working in mental health across inpatient and community settings. He was previously employed by the NHS within an ADHD service, managing a caseload of patients and providing medication initiation, review and dose titration. Bolu currently works as Lead Pharmacist for Neurodevelopmental and Learning Disabilities Services (NLDS) at North East London Foundation Trust, where he is strategic and operational lead for the ADHD pathway. He has also worked as a Specialist Mental Health Pharmacist within the same Trust, as an Independent Prescriber with ADHD Care, and as a rotational pharmacist at Basildon University Hospital. Bolu has experience working with adults, children and young people across a wide range of mental and physical health conditions. His areas of specialism include: Psychopharmacological management of ADHD Neurodevelopmental conditions including ADHD and ASD Providing medicines information and advice in response to complex enquiries Creating shared-care arrangements with GPs for continued medication Medicines management: promoting medicines optimisation and tackling polypharmacy